Lipocine (NASDAQ:LPCN)‘s stock had its “buy” rating reaffirmed by investment analysts at Ladenburg Thalmann Financial Services in a report released on Thursday, The Fly reports. They currently have a $11.00 price objective on the specialty pharmaceutical company’s stock. Ladenburg Thalmann Financial Services’ price target points to a potential upside of 217.92% from the stock’s current price.
Several other equities research analysts have also recently commented on LPCN. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Lipocine in a report on Friday, December 8th. Canaccord Genuity reaffirmed a “buy” rating and issued a $11.00 price target on shares of Lipocine in a report on Tuesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $17.50.
Shares of Lipocine (NASDAQ:LPCN) opened at $3.46 on Thursday. Lipocine has a fifty-two week low of $2.90 and a fifty-two week high of $5.33. The company has a market capitalization of $73.34, a P/E ratio of -3.60 and a beta of 0.11.
ILLEGAL ACTIVITY WARNING: This story was reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.themarketsdaily.com/2018/01/11/ladenburg-thalmann-financial-services-reaffirms-buy-rating-for-lipocine-lpcn.html.
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.